Transition metal-catalysed bioorthogonal reactions are severely hindered in biomedical applications, mainly due to a lack of target specificity. Now, research shows that a trojan exosome vesicle can deliver a palladium catalyst specifically to progenitor cells for bioorthogonal catalysis, allowing localized prodrug activation.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Catalytically potent and selective clusterzymes for modulation of neuroinflammation through single-atom substitutions
Nature Communications Open Access 07 January 2021
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Sletten, E. M. & Bertozzi, C. R. Angew. Chem. Int. Ed. 48, 6974–6998 (2009).
Soldevila-Barreda, J. J. & Metzler-Nolte, N. Chem. Rev. 119, 829–869 (2019).
Ji, X. et al. Chem. Soc. Rev. 48, 1077–1094 (2019).
Wang, F., Zhang, Y., Du, Z., Ren, J. & Qu, X. Nat. Commun. 9, 1209 (2018).
Sancho-Albero, M. et al. Nat. Catal. https://doi.org/10.1038/s41929-019-0333-4 (2019).
Alvarez-Erviti, L. et al. Nat. Biotechnol. 29, 341–345 (2011).
Dong, H. et al. Anal. Chem. 90, 4507–4513 (2018).
Ngo, A. H., Bose, S. & Do, L. H. Chem. Eur. J. 24, 10584–10594 (2018).
About this article
Cite this article
Du, Z., Qu, X. Exosomes for cell-targeted bioorthogonal catalysis. Nat Catal 2, 837–838 (2019). https://doi.org/10.1038/s41929-019-0350-3